Zoetis has announced that Apoquel, its fast-acting oral therapy for canine pruritus, has resumed full UK distribution.
The company has upscaled its manufacturing of the product after experiencing 'unprecedented' levels of demand for Apoquel since its launch last year. As such, it has implemented various safeguards over the past 18 months to better align supply with demand.
“Zoetis has resumed full UK distribution of its canine pruritus treatment Apoquel after upscaling its production capabilities for the product.“
For example, an allocation system was established to ensure that those dogs that had started on Apoquel were able to remain on the medicine for as long as their vet deemed appropriate.
Since then, Zoetis has reduced the length of time it takes to manufacture the product and added further production capacity.
Ned Flaxman, companion animal business unit director at Zoetis, said: "We're looking forward to a very good Christmas and new year with Apoquel fully back in stock, and we'd like to thank all of our customers for their patience."
Apoquel is the first janus kinase (JAK) inhibitor therapy approved for veterinary use, providing rapid and sustained relief of pruritus and improving skin lesions.See all the latest jobs in Animal Health